Chemotherapy Indications for Breast Cancer

Introduction to Chemotherapy Guidelines

The European Society for Medical Oncology recommends chemotherapy for all triple-negative breast cancers, all HER2-positive tumors, all node-positive disease regardless of subtype, and for hormone receptor-positive/HER2-negative cancers based on individual relapse risk assessment 1, 2

All triple-negative breast cancers benefit from adjuvant chemotherapy, with the possible exception of very low-risk special histological subtypes such as medullary or adenoid cystic carcinomas 1
Standard regimens consist of 4-8 cycles of anthracycline- and/or taxane-based chemotherapy, with sequential administration of anthracyclines followed by taxanes being the recommended approach 1
For metastatic triple-negative disease with PD-L1 positivity, add immune checkpoint inhibitors (atezolizumab plus nab-paclitaxel or pembrolizumab plus chemotherapy) as first-line therapy 3, 4

The American Society of Clinical Oncology recommends all HER2-positive tumors require chemotherapy combined with trastuzumab, regardless of hormone receptor status 1, 5
For HER2-positive/hormone receptor-positive (triple-positive) disease: Use anthracycline-taxane sequence plus trastuzumab plus endocrine therapy 5
Trastuzumab should be administered concurrently with taxanes (not anthracyclines) and continued for one year total 1, 5
Trastuzumab combined with chemotherapy approximately halves recurrence risk and improves overall survival compared to chemotherapy alone 1

The National Comprehensive Cancer Network recommends the decision to add chemotherapy to endocrine therapy depends on relapse risk, presumed endocrine responsiveness, and patient preferences 1
For node-positive disease, all patients require chemotherapy regardless of hormone receptor status (Category 1 recommendation) 2
For tumors ≤0.5 cm: Endocrine therapy alone is sufficient; chemotherapy provides minimal incremental benefit 2
For larger node-negative tumors, chemotherapy indications depend on degree of hormone receptor expression, tumor grade and proliferation, and tumor size 1, 2, 6

Standard adjuvant chemotherapy consists of 4-8 cycles (12-24 weeks) of anthracycline- and/or taxane-based regimens, with sequential rather than concomitant administration 1
Anthracyclines are recommended for all patients, especially those with HER2-positive disease 6
Taxanes should be limited to high-risk patients 6
Dose-dense schedules with G-CSF support should be considered for highly proliferative tumors 5

For hormone receptor-positive metastatic disease, single-agent chemotherapy is preferred over combination chemotherapy, although combination regimens may be offered for highly symptomatic or immediately life-threatening disease 3, 4
Patients with disease progression on endocrine therapy may be offered either continued endocrine therapy with or without targeted agents, or single-agent chemotherapy 3, 4
For patients with germline BRCA mutations no longer benefiting from endocrine therapy, PARP inhibitors are preferred over chemotherapy 3, 4